Kaiyuan Pharmaceutical

Zhejiang Kaiyuan Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, and large-scale manufacturing of active pharmaceutical ingredients (APIs) and high-end chemical intermediates. The company has established a significant market presence in the production of antiviral, cardiovascular, and antidiabetic agents, with a particular focus on nucleoside analogues. Operating as both a manufacturer and a CDMO partner, Kaiyuan Pharmaceutical maintains multiple production bases that adhere to international GMP standards. Their product portfolio includes key treatments for Hepatitis B and influenza, serving both domestic and international markets. The company is recognized for its strong R&D capabilities in complex chemical synthesis and its commitment to high-quality pharmaceutical manufacturing.